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abstract
PURPOSE Recently, we have shown that metastasis-free survival is a strong surrogate for overall survival (OS) in
men with intermediate- and high-risk localized prostate cancer and can accelerate the evaluation of new (neo)
adjuvant therapies. Event-free survival (EFS), an earlier prostate-specific antigen (PSA)–based composite end
point, may further expedite trial completion.
METHODS EFS was defined as the time from random assignment to the date of first evidence of disease
recurrence, including biochemical failure, local or regional recurrence, distant metastasis, or death from any
cause, or was censored at the date of last PSA assessment. Individual patient data from trials within the In-
termediate Clinical Endpoints in Cancer of the Prostate–ICECaP–database with evaluable PSA and disease
follow-up data were analyzed. We evaluated the surrogacy of EFS for OS using a 2-stage meta-analytic validation
model by determining the correlation of EFS with OS (patient level) and the correlation of treatment effects
(hazard ratios [HRs]) on both EFS and OS (trial level). A clinically relevant surrogacy was defined a priori as an
R2 $ 0.7.
RESULTS Data for 10,350 patients were analyzed from 15 radiation therapy–based trials enrolled from 1987 to
2011 with a median follow-up of 10 years. At the patient level, the correlation of EFS with OS was 0.43 (95% CI,
0.42 to 0.44) as measured by Kendall’s tau from a copula model. At the trial level, theR2 was 0.35 (95% CI, 0.01
to 0.60) from the weighted linear regression of log(HR)-OS on log(HR)-EFS.
CONCLUSION EFS is a weak surrogate for OS and is not suitable for use as an intermediate clinical end point to
substitute for OS to accelerate phase III (neo)adjuvant trials of prostate cancer therapies for primary radiation
therapy–based trials.
J Clin Oncol 38:3032-3041. © 2020 by American Society of Clinical Oncology
INTRODUCTION
Despite various strategies for the early detection of
prostate cancer, more than one half of all deaths occur
in men who initially presented with localized disease.1
Curing metastatic prostate cancer is still a formidable
challenge, and the most likely near-term strategy to
substantially decrease the approximately 300,000
prostate cancer deaths that occur worldwide from the
1.1 million newly diagnosed cases is by preventing
relapses from intermediate- and high-risk localized
disease with more effective (neo)adjuvant systemic
therapy.2-5
Improvements in systemic therapies increase the
longevity of some men with metastatic hormone-
sensitive prostate cancer and castration-resistant pros-
tate cancer (CRPC).6-18 When metastases are occult
to conventional computerized tomography and
technetium bone-scan imaging, they are more sen-
sitive to testosterone-suppression therapy, resulting
in an increase in the chance of cure when systemic
therapies are given with local therapy.5,19,20 Potential
eradication of micrometastases with new thera-
pies may further decrease the number of men
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quintessential end point of overall survival (OS) is used
as the primary end point, (neo)adjuvant prostate cancer
clinical trials usually take longer than a decade to be
reported.
Recently, the Intermediate Clinical Endpoints in Cancer of
the Prostate (ICECaP) working group has shown that
metastasis-free survival (MFS: metastasis on conventional
imaging or death from any cause) is a strong surrogate for
OS in localized prostate cancer trials.21 For new treatments
with an anticipated treatment effect size that will decrease
the rate of metastases by . 33% (ie, hazard ratio [HR]
, 0.67), MFS as the primary end point can shorten the time
to show an OS benefit.21 Disease-free survival (DFS), which
is MFS plus local-regional recurrence events, is not as
strong a surrogate for OS.
Use of an earlier intermediate clinical end point (ICE) in-
cluding prostate-specific antigen (PSA) recurrence could
result in even more expeditious adjuvant trial conduct than
DFS or MFS. However, for an ICE to serve as a good
surrogate for OS, there must be no confounding from
salvage therapy for relapsed disease that can either cure
the disease and/or prolong postrelapse survival to the
point that competing risks of death affect the analysis.22-27
Salvage prostate bed radiation after a prostatectomy and
the prolonged survival of patients treated with androgen
deprivation therapy (ADT) for biochemical recurrence
(BCR) are potential confounders for prostate cancer
outcomes. Prior studies have shown PSA nadir, end of
treatment PSA, time to BCR, and post-BCR PSA doubling
time (PSA-DT), are prognostic for OS and have some
surrogacy at the patient level.28-31 However, to our
knowledge, no prior studies using individual patient data
(IPD) from multiple studies have been conducted to
assess trial-level surrogacy, which evaluates whether
a treatment effect on the ICE (eg, time to BCR) is correlated
with the treatment effect on the ultimate end point (ie, OS)
across many trials.
We hypothesized that event-free survival (EFS), which in-
cludes all components of DFS plus PSA-only relapse, may
be a surrogate for OS at both the patient and the trial level.
We also assessed the surrogacy of EFS for MFS, because
MFS is a strong surrogate for OS. Given the observation that
most patients with intermediate- or high-risk localized
prostate cancer are cured, and even if they relapse with
a rising PSA, often die as a result of a nonprostate cancer




Eligible trials were identified from the established ICECaP
data repository, composed of 22,825 IPD from 28 ran-
domized trials conducted in Australia, Canada, Europe,
New Zealand, and the United States for localized prostate
cancer.1 For this analysis, eligible trials included radiation
therapy as primary therapy that had evaluable PSA and
disease follow-up data suitable for EFS analysis (see end
point definitions). Prostatectomy-based trials were not in-
cluded because of a lack of evaluable PSA data.
Definition of End Points
EFS was measured from the date of random assignment to
the date of first evidence of disease recurrence, including
biochemical failure, local or regional recurrence, distant
metastasis, or death from any cause, or was censored at the
date of last PSA assessment. Death without prior disease
recurrence was also censored at the last PSA assessment if
the interval between the last PSA assessment and the date
of death was . 15 months. MFS was measured from the
date of random assignment to the date of the first evidence
of recorded distant metastases or death from any cause, or
was censored at the date of last follow-up. OS was mea-
sured from the date of random assignment to death from
any cause and censored at the date of last follow-up in
CONTEXT
Key Objectives
To determine whether event-free survival (EFS), an early prostate-specific antigen (PSA)–based composite end point can be
used as an intermediate clinical end point and serve as a surrogate for overall survival (OS) in localized prostate cancer. If
surrogacy was established, the secondary objective was to detail how to deploy EFS as an end point to expedite
completion of randomized phase III clinic trials in this setting.
Knowledge Generated
EFS has very a low correlation with OS in men with localized prostate cancer treated with radiation, and is there-
fore a weak surrogate for OS.
Relevance
Unlike metastasis-free survival, EFS is not suitable for use as an intermediate clinical end point to substitute for OS to
accelerate phase III (neo)adjuvant trials of prostate cancer therapies for primary radiation therapy–based trials. Research
is ongoing and needed to quantify other clinical benefits from preventing a PSA relapse in this setting.
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surviving patients. Time to event (TTE), time to metastasis
(TTM), and DSS were defined analogously to EFS, MFS,
and OS, respectively, but patients with nonprostate deaths
had end points censored or considered as competing risk in
sensitivity analyses.
Biochemical failure was defined according to the
2006 RTOG-ASTRO Phoenix definition. A PSA rise by
$ 2 ng/mL above the nadir was considered biochemical
failure; patients not fully meeting the PSA criteria for failure
who underwent subsequent therapy were also declared to
be failures at the time of salvage initiation. Of the 15 in-
cluded trials, 14 trials were viable for harmonization by the
Phoenix definition and 1 trial used the ASTRO definition
(Data Supplement, online only). Local or regional re-
currence was based on trial-defined events; distant me-
tastasis was confirmed by imaging or histologic evidence as
described in our prior MFS analysis.21
Statistical Analyses
Surrogacy criteria. We evaluated the surrogacy of EFS with
OS using a 2-stage meta-analytic validation model as de-
scribed previously.32 Two conditions must hold to claim
EFS is a surrogate for OS. Condition 1 requires EFS and OS
to be correlated. Condition 2 requires that the treatment
effects on both end points be correlated. The validity of the
surrogate is reflected by the strength of both correlations.
To be consistent with our previous work and other surro-
gacy assessments in oncology, we defined a priori a clini-
cally relevant surrogacy as R2 $ 0.7.1,21
Condition 1 was tested at both the patient and the trial level.
At the patient level, associations of OS with EFS were
evaluated via a bivariate copula model over the entire
follow-up of IPD (Data Supplement). Kendall’s tau (range,
0-1) quantified the correlation between end points. At the
trial level, we first obtained Kaplan-Meier estimates of
5-year EFS and 8-year OS rates for each treatment arm
within each trial. We then performed weighted linear re-
gression (WLR) of trial- and arm-specific 8-year OS rates on
5-year EFS rates. Similar analyses were performed at an
earlier milestone time: OS rates at 5 years on EFS rates at
3 years. These time points were chosen because they are
reported frequently in the literature and reflect the earlier
time of biochemical failures. Regressions were weighted by
A
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FIG 1. (A) Kaplan-Meier estimates of overall survival (OS), metastasis-free survival (MFS), and event-free survival (EFS) where non–prostate cancer deaths
were counted as events. (B) Kaplan-Meier estimates of disease-specific survival (DSS), time to metastasis (TTM), and time to event (TTE) where non–prostate
cancer deaths were censored. (C) Estimated hazard functions over time for OS, MFS, and EFS. (D) Estimated hazard functions over time for DSS, TTM, and
TTE. Median follow-up was 10 years.
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the inverse of variances of the 5- or 3-year estimates of EFS.
R2 was used to quantify the proportion of variance that was
explained by the regressions.
Condition 2 was tested at the trial level. Proportional haz-
ards models estimated the study-specific treatment effects
(ie, the natural log[HR] of the experimental v the control
arm) on the EFS and OS. We then fit a WLR of log(HR)-OS
on log(HR)-EFS across trials. Regressions were weighted by
inverse variances of the log(HR)-EFS. The same approach
was applied to the surrogacy analysis of EFS for MFS, and
the surrogacy of TTE for TTM and DSS, where end points of
patients with nonprostate cancer deaths were censored.
Subgroup and sensitivity analysis. We conducted pre-
planned subgroup analyses by age (, 70 years,$ 70 years),
by duration of ADT (None, 3-8months,$ 2 years), by patient
risk groups (defined by the National Comprehensive Cancer
Network [NCCN] or D’Amico’s criteria), and by biochemical
failure criteria (Phoenix definition only). Because a large
proportion of OS events were non–prostate cancer deaths,
we performed sensitivity analyses to estimate the trial-level
correlation between cumulative incidence estimates of TTE
and DSS, and between the subdistribution treatment effect
HR estimates for TTE and DSS from competing risk models,
for which non–prostate cancer deaths were considered to be
the competing risk for each end point. Model accuracy was
assessed by the leave-one-out cross validation approach
(Data Supplement).
Surrogate threshold effect. The surrogate threshold effect
(STE) is defined as the minimum treatment effect on the
surrogate (HR-EFS) necessary to predict a significant OS
benefit, corresponding to the upper 95% prediction limit for
OS HR lower than 1 (Data Supplement). All analyses were

































































































FIG 2. Bubble plot and regression of (A) overall survival (OS) at 8 years on event-free survival (EFS) at 5 years; (B) metastasis-free survival (MFS) at
5 years on EFS at 3 years; (C) disease-specific survival (DSS) at 8 years on time to event (TTE) at 5 years; and (D) time to metastasis (TTM) at 5 years
on TTE at 3 years. All rates were Kaplan-Meier estimates by trial and treatment arm. Circle size and regression were weighted by inverse variance of
the 5- or 3-year estimate for EFS and TTE.
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RESULTS
Trial and Patient Characteristics
For analysis, 10,350 patients from 15 primary radiation
therapy–based trials were included (Data Supplement).
One trial was split into 2 experimental arms, which resulted
in 16 study units for EFS and OS analysis and 13 study units
for MFS analysis (Data Supplement). Most trials compared
the duration of ADT (10 trials) or different radiation doses or
fields (4 trials). Patients enrolled in the trials from 1987 to
2011, and the median follow-up was 10 years (range, 0.1-
22 years). More than 80% of patients were , 75 years of
age, and nearly 60% had high-risk disease according to the
NCCN or D’Amico criteria (Data Supplement).
For the EFS end point, 6,049 events were reported, 4,666
(77%) from disease recurrence (biochemical failure only
56%; the following were with or without reported bio-
chemical failure: local or regional recurrence, 12%; distant
metastasis, 6%; and unknown recurrence site, 3%) and
23% from nonprostate cancer death (Data Supplement). The
median duration of EFS from random assignment was
6.0 years (95% CI, 5.9 to 6.2 years). There were 4,390 events
for the MFS end point: 29% metastasis, 5% prostate cancer
death without recoded metastasis, and 66% non–prostate
cancer death. Observed 5-year rates from the Kaplan-Meier
curves were 56% (95% CI, 55% to 57%) for EFS,
80% (95% CI, 79% to 81%) for MFS, and 84% (95% CI,
84% to 85%) for OS (Fig 1). Cumulative event rates for disease
recurrence, metastasis, and prostate cancer death compared
with non–prostate cancer death were delineated for the overall
cohort and by the NCCN risk group and age group (Data
Supplement). For patients who experienced an EFS disease
recurrence event (n 5 4,666 of the 6,049 events), median
postrecurrence OS was 7.4 years (95% CI, 7.1 to 7.7
years). For patients who were reported to have a metastasis
(n 5 1,287 of 4,390 MFS events), median postmetastasis
survival was 1.9 years (95% CI, 1.8 to 2.1 years).
Surrogacy Condition 1: Correlation Between ICE and OS
At the patient level, the Kendall’s tau correlation over the entire
follow-upwas 0.43 (95%CI, 0.42 to 0.44) for EFSwith OS and
0.51 (95% CI, 0.49 to 0.52) for EFS with MFS. When non–
prostate cancer deaths were censored, the correlations of TTE
TABLE 1. Surrogacy Condition 1: Correlation Between Clinical End Points (correlation using patient-level data)
Correlation Using Patient-Level Data No. of Trials No. of Patients Kendall’s Tau (95% CI)
When non-CaP deaths were counted as events
Correlation of OS and EFS 16 10,350 0.43 (0.42 to 0.44)
Correlation of MFS and EFS 13a 9,481 0.51 (0.49 to 0.52)
When non-CaP deaths were censored
Correlation of DSS and TTE 14b 9,934 0.52 (0.50 to 0.54)
Correlation of TTM and TTE 13a 9,481 0.53 (0.51 to 0.55)
Abbreviations: CaP, cancer of the prostate; DSS, disease-specific survival; EFS, event-free survival; MFS, metastasis-free survival; OS, overall
survival; TTE, time to event; TTM, time to metastasis.
aExcluding 3 studies that did not collect metastasis data.
bExcluding 2 studies with , 3 prostate cancer deaths.
TABLE 2. Surrogacy Condition 1: Correlation Between Clinical End Points (regression using trial level estimates)
Regression Using Trial-Level Estimates No. of Trials No. of Arms R2 (95% CI)
When non-CaP deaths were counted as events
8-year OS rate on 5-year EFS rate 14b 28 0.55 (0.26 to 0.70)
8-year MFS rate on 5-year EFS rate 11a,b 22 0.63 (0.31 to 0.76)
5-year OS rate on 3-year EFS rate 16 32 0.61 (0.35 to 0.73)
5-year MFS rate on 3-year EFS rate 13a 26 0.73 (0.48 to 0.82)
When non-CaP deaths were censored
8-year DSS on 5-year TTE rate 14b 28 0.45 (0.15 to 0.63)
8-year TTM on 5-year TTE rate 11a,b 22 0.49 (0.15 to 0.67)
5-year DSS on 3-year TTE rate 16 32 0.44 (0.17 to 0.62)
5-year TTM on 3-year TTE rate 13a 26 0.57 (0.27 to 0.72)
Abbreviations: CaP, cancer of the prostate; DSS, disease-specific survival; EFS, event-free survival; MFS, metastasis-free survival; OS, overall
survival; TTE, time to event; TTM, time to metastasis.
aExcluding 3 studies that did not collect metastasis data.
bExcluding 2 studies with median follow-up of , 6 years.
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with DSS and with TTMwere 0.52 (95%CI, 0.50 to 0.54) and
0.53 (95% CI, 0.51 to 0.55), respectively.
The end point correlation was also tested using trial-level
estimates (Fig 2). The R2 was 0.55 (95% CI, 0.26 to 0.70)
from WLR of 8-year OS on 5-year EFS rates and was 0.63
(95% CI, 0.31 to 0.76) of 8-year MFS on 5-year EFS rates
across trials and treatment arms. With earlier milestone
time points of 5-year OS and MFS rates versus 3-year EFS
rates, R2 was 0.61 (95% CI, 0.35 to 0.73) and 0.73
(95% CI, 0.48 to 0.82), respectively. Tables 1 and 2 also
summarize R2 for these end points when non–prostate
cancer deaths were censored.
Surrogacy Condition 2: Correlation Between Treatment
Effect on ICE and OS
At the trial level, trial-specific treatment effects, measured
by log-HR for each end point, are shown in forest plots in
the Data Supplement. The R2 from the WLR of log(HR)-OS
on log(HR)-EFS was 0.35 (95% CI, 0.01 to 0.60) and was
0.55 (95% CI, 0.09 to 0.74) for log(HR)-MFS on log(HR)-
EFS (Table 3). When non–prostate cancer deaths were
censored, the R2 of log(HR)-DSS on log(HR)-TTE was 0.39
(95% CI, 0.01 to 0.64) and was 0.68 (95% CI, 0.23 to 0.81)
for log(HR)-TTM on log(HR)-TTE (Fig 3).
Subgroup and Sensitivity Analysis
At the patient level, results were consistent when the
analysis was restricted to the 14 trials using the Phoenix
definition for biochemical failure, or to the populations
with high-risk features or above and below the median
age of 70 years (Data Supplement). The Kendall’s tau
correlation between OS and EFS was slightly stronger in
those who received $ 2 years of ADT compared with
those who received short-term or no (neo)adjuvant ADT
(0.53, 0.43, and 0.39, respectively). In patients with
high-risk features and when non–prostate cancer deaths
were censored, the estimated R2 from the WLR of
log(HR)-DSS on log(HR)-TTE across trials was 0.64
(95% CI, 0.21 to 0.79). Results were also consistent in
a WLR analysis of trial-level correlations when non–
prostate cancer deaths were treated as competing risk
(Data Supplement) and in leave-one-out cross-validation
(Data Supplement).
STE
The STE was an HR(EFS) of 0.33 on OS (Fig 3A) and an
HR(EFS) of 0.44 on MFS (Fig 3B), which indicates that
large risk reductions of at least 67% and 56% on EFS would
predict a significant treatment effect on OS and MFS, re-
spectively. The STE was an HR(TTE) of 0.29 on DSS
(Fig 3C) and an HR(TTE) of 0.48 on TTM (Fig 3D) when
non–prostate cancer deaths were censored.
DISCUSSION
This work clearly shows that EFS is a weak surrogate for
both OS and DSS for men with intermediate- and high-risk
localized prostate cancer treated with curative-intent ra-
diation with a 10% chance of dying as a result of prostate
cancer and approximately a 60% OS at 10 years. Notably,
this analysis included only patients treated with primary
radiation, and therefore, the findings should not be ex-
trapolated to trials of patients treated with prostatectomy or
salvage radiation after prostatectomy26. As the estimated
hazard curves over time (Fig 1) depict, there are many early
EFS events (mostly PSA relapses) with few MFS and OS
events. This indicates that despite 80% of men being
younger than 75 years old and fit for a clinical trial, they are
still more likely to die a non–prostate cancer death even if
they have a PSA relapse. This provides additional evidence
that many PSA relapses are indolent and/or are controlled
by testosterone suppression.34,35
Prior studies have shown PSA relapse heralding a prostate
cancer recurrence is prognostic for OS and DSS, mainly
on the basis of single-trial, patient-level data and using
landmark analysis at selected time points.29-31 In partic-
ular, the subpopulation of younger men with a rapidly
rising PSA at relapse are more likely to die as a result of
prostate cancer. However, the new data presented in this
manuscript showing the low correlation of EFS with OS at
both the patient and the trial level indicate that EFS is not
a viable surrogate for OS to replace it as the primary end
point in phase III localized prostate cancer trials. This was
TABLE 3. Surrogacy Condition 2: Treatment Effects on End Points are Correlated
Regression Analysis Details No. of trials R 2 (95% CI) Regression Equation
When non-CaP deaths were counted as events
Regression of Log(HR)-OS on Log(HR)-EFS 16 0.35 (0.01 to 0.60) Log(HR)OS 5 0.0047 1 0.3470 3 Log(HR)EFS
Regression of Log(HR)-MFS on Log(HR)-EFS 13a 0.55 (0.09 to 0.74) Log(HR)MFS 5 0.0449 1 0.4978 3 Log(HR)EFS
When non-CaP deaths were censored
Regression of Log(HR)-DSS on Log(HR)-TTE 14b 0.39 (0.01 to 0.64) Log(HR)DSS 5 20.0118 1 0.7554 3 Log(HR)TTE
Regression of Log(HR)-TTM on Log(HR)-TTE 13a 0.68 (0.23 to 0.81) Log(HR)TTM 5 0.0443 1 0.7567 3 Log(HR)TTE
Abbreviations: DSS, disease-specific survival; EFS, event-free survival; MFS, metastasis-free survival; OS, overall survival; TTE, time to event;
TTM, time to metastasis.
aExcluding 3 studies that did not collect metastasis data.
bExcluding 2 studies with , 3 prostate cancer deaths.
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underscored by showing that removal of non–prostate
cancer deaths (approximately 20% of EFS events) as part
of the TTE analysis did not substantially improve the
correlation. By contrast, MFS was a strong surrogate for
OS in the same population treated with radiation (with all
surrogacy association parameters . 0.8).21 EFS may play
a role in enriching the analysis or the interim monitoring
analysis during phase III clinical trials.36 This finding does
not undermine the observation that identification of PSA
relapses has other benefits such as identifying men for
postprostatectomy salvage radiation and use of PSA-DT
for counseling about prognosis. The long-term results of
ongoing (neo)adjuvant trials with potent androgen re-
ceptor inhibitors will determine whether EFS can serve as
a surrogate for OS in this setting. This possibility is further
confounded by the fact this class of therapy may directly
affect the biomarker (PSA).
It is also recognized that there are other benefits to patients
and society from not having a PSA relapse. From the patient
perspective, there is the potential impairment in quality of
life associated with a PSA relapse, both from the anxiety of
the recurrence itself and from the adverse effects of salvage
radiation therapy (if treated with a prostatectomy) and pro-
tracted testosterone suppression, noting the median post-
recurrence survival in this cohort was 7.4 years. In addition,
there are the patient and health care impacts from increasing
comorbidities associated with prolonged ADT such as glu-
cose intolerance, cardiovascular events, and bone loss. If
a patient does progress to having metastatic disease, there
are additional impairments from cancer-related events of
bone pain and fatigue and the costs and toxicities of more
potent hormonal therapy and cytotoxic agents.37 Recent
modeling analyses from the STAMPEDE docetaxel results
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FIG 3. Bubble plot and regression of (A) hazard ratio for overall survival (OS-HR) on hazard ratio for event-free survival (EFS-HR); (B) hazard ratio for
metastasis-free survival (MFS-HR) on EFS-HR; (C) hazard ratio for disease-specific survival (DSS-HR) on hazard ratio for time to event (TTE-HR); (D) hazard
ratio for time to metastasis (TTM-HR) on TTE-HR. Cox proportional hazards regression estimated HR for each study, and values were natural logarithm
transformed. Circle size and regression were weighted by inverse variance of log(HR) estimates for EFS or TTE. The orange lines display surrogate threshold
effect (STE), which is the intersection of the upper 95% prediction limit with the horizontal line representing an HR of 1 for the true end points.
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also a more efficient use of health care resources.38 The
ICECaP Working Group has established a health economics
team who are using the ICECaP IPD to estimate the health
economic impacts on patients and society of preventing
metastatic disease and earlier PSA relapse. If these benefits
of preventing earlier relapses can be defined at both the
patient and the societal level, and they offset the associated
costs from the use of the new therapies in the (neo)adjuvant
setting, then PSA-based end points could be used to ac-
celerate the conduct of adjuvant prostate cancer trials.
The inherent limitations of this work are as follows. First, the
data were generated from an era before the use of the more
active therapies shown to prolong OS in the metastatic
hormone-sensitive prostate cancer and CRPC settings.6-9,17,18
However, a recent analysis indicates that the cumulative
use and efficacy of these new therapies have a limited
impact on CRPC longevity.39 It is hoped that some of these
new therapies will have more impact in the adjuvant
setting. Second, because of incomplete PSA or salvage
therapies, only a subset of all the trials in the ICECaP
database was included in the EFS analysis, and these were
only radiation-based trials. However, the analyzed IPD from
10,000 patients was representative of both the entire ICECaP
database (Data Supplement) and the general population of
patients with intermediate- or high-risk prostate cancer
treated with radiation,1 which supports the relevance of the
results. Another notable limitation is the lack of granular
testosterone and PSA data to assess doubling time before
subsequent therapies; this highlights the need for a har-
monized and strategic data collection plan for future trials
to robustly assess other PSA metrics.40
In conclusion, EFS is only a weak surrogate for OS in
clinically localized prostate cancer in a patient population
treated with radiation with approximately a 10% chance of
dying of prostate cancer over 10 years despite potentially
curative local therapy. As such, EFS cannot be used as
a surrogate for OS and replace it as the primary end point to
accelerate (neo)adjuvant prostate cancer phase III trials.
Health economic analyses are underway to determine if
other metrics of benefits to patients and society can be
quantified to support the use of EFS as an end point to
accelerate (neo)adjuvant prostate cancer trials.
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Brussels, Belgium
23Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne,
Australia
24Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute,
Boston, MA
CORRESPONDING AUTHOR
Christopher J. Sweeney, MBBS, Dana-Farber Cancer Institute, 450
Brookline Ave, Boston, MA 02215; e-mail: christopher_sweeney@
dfci.harvard.edu.
SUPPORT
Supported by a Prostate Cancer Foundation Challenge Award and by
grants from Astellas/Pfizer, Janssen, Takeda, Sotio, Sanofi, Bayer, and
Dendreon.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF
INTEREST AND DATA AVAILABILITY STATEMENT
Disclosures provided by the authors and data availability statement (if
applicable) are available with this article at DOI https://doi.org/10.1200/
JCO.19.03114.
AUTHOR CONTRIBUTIONS
Conception and design: Wanling Xie, Meredith M. Regan, Marc Buyse,
Susan Halabi, Oliver Sartor, Howard Soule, Mario Eisenberger, Nicholas
James, Silke Gillessen, Wendy Parulekar, Bertrand Tombal, Scott
Williams, Christopher J. Sweeney
Financial support: Howard Soule, Christopher J. Sweeney
Administrative support: Christopher J. Sweeney
Provision of study material or patients: Noel Clarke, Anthony D’Amico,
James Dignam, Nicholas James, Karim Fizazi, Nicolas Mottet, Wendy
Parulekar, Matthew R. Sydes, Christopher J. Sweeney, ICECaP Working
Group
Collection and assembly of data: Meredith M. Regan, Laurence Collette,
James Dignam, Nicholas James, Karim Fizazi, Wendy Parulekar, Howard
Sandler, Matthew R. Sydes, Bertrand Tombal, Christopher J. Sweeney
Data analysis and interpretation: Wanling Xie, Meredith M. Regan, Marc
Buyse, Susan Halabi, Philip W. Kantoff, Oliver Sartor, Donald Berry, Noel
Journal of Clinical Oncology 3039
PSA is not a Surrogate for OS in Localized Prostate Cancer
Clarke, Laurence Collette, Anthony D’Amico, Richard De Abreu
Lourenco, James Dignam, Mario Eisenberger, Nicholas James, Karim
Fizazi, Silke Gillessen, Yohann Loriot, Nicolas Mottet, Wendy Parulekar,
Daniel E. Spratt, Matthew R. Sydes, Scott Williams, Christopher
J. Sweeney
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors
ACKNOWLEDGMENT
We thank Victoria Wong, Frontier Science & Technology Research
Foundation, for computer programming. We also thank the Writing
Committee and ICECaP Working Group for all of their contributions (see
Appendix for details).
REFERENCES
1. Sweeney C, Nakabayashi M, Regan M, et al: The development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). J Natl Cancer Inst 107:
djv261, 2015
2. Torre LA, Bray F, Siegel RL, et al: Global cancer statistics, 2012. CA Cancer J Clin 65:87-108, 2015
3. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2016. CA Cancer J Clin 66:7-30, 2016
4. Bolla M, Gonzalez D, Warde P, et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med
337:295-300, 1997
5. Denham JW, Steigler A, Lamb DS, et al: Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from
the TROG 96.01 randomised trial. Lancet Oncol 12:451-459, 2011
6. Kyriakopoulos CE, Chen YH, Carducci MA, et al: Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: Long-term survival analysis of the
randomized phase III E3805 CHAARTED trial. J Clin Oncol 36:1080-1087, 2018
7. James ND, de Bono JS, Spears MR, et al: Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377:338-351, 2017
8. James ND, Sydes MR, Clarke NW, et al: Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE):
Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387:1163-1177, 2016
9. Fizazi K, Tran N, Fein L, et al: Abiraterone plus orednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377:352-360, 2017
10. Fizazi K, Scher HI, Molina A, et al: Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the
COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13:983-992, 2012
11. Ryan CJ, Smith MR, Fizazi K, et al: Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-
resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16:
152-160, 2015
12. Beer TM, Armstrong AJ, Rathkopf DE, et al: Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424-433, 2014
13. de Bono JS, Oudard S, Ozguroglu M, et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after
docetaxel treatment: A randomised open-label trial. Lancet 376:1147-1154, 2010
14. Tannock IF, deWit R, Berry WR, et al: Docetaxel plus prednisone ormitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004
15. Parker C, Nilsson S, Heinrich D, et al: Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213-223, 2013
16. Kantoff PW, Higano CS, Shore ND, et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422, 2010
17. Davis ID, Martin AJ, Stockler MR, et al: Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 381:121-131, 2019
18. Chi KN, Agarwal N, Bjartell A, et al: Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 381:13-24, 2019
19. Bolla M, Collette L, Blank L, et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate
cancer (an EORTC study): A phase III randomised trial. Lancet 360:103-106, 2002
20. D’Amico AV, Chen MH, Renshaw AA, et al: Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial. JAMA 299:289-295,
2008
21. Xie W, Regan MM, Buyse M, et al: Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J Clin Oncol 35:3097-3104, 2017
22. Hamdy FC, Donovan JL, Lane JA, et al: 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375:1415-1424, 2016
23. Bill-Axelson A, Holmberg L, Garmo H, et al: Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 370:932-942, 2014
24. Crook JM, O’Callaghan CJ, Duncan G, et al: Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 367:895-903, 2012
[Erratum: N Engl J Med 367:2262, 2012]
25. Ross AE, Yousefi K, Davicioni E, et al: Utility of risk models in decision making after radical prostatectomy: Lessons from a natural history cohort of intermediate-
and high-risk men. Eur Urol 69:496-504, 2016
26. Shipley WU, Seiferheld W, Lukka HR, et al: Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med 376:417-428, 2017
27. Broglio KR, Berry DA: Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 101:1642-1649, 2009
28. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1597, 1999
29. Dignam JJ, Hamstra DA, Lepor H, et al: Time interval to biochemical failure as a surrogate end point in locally advanced prostate cancer: Analysis of randomized
trial NRG/RTOG 9202. J Clin Oncol 37:213-221, 2019
30. Royce TJ, ChenMH,Wu J, et al: Surrogate end points for all-causemortality in men with localized unfavorable-risk prostate cancer treated with radiation therapy
vs radiation therapy plus androgen deprivation therapy: A secondary analysis of a randomized clinical trial. JAMA Oncol 3:652-658, 2017
31. D’Amico AV, Chen MH, de Castro M, et al: Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in
men with localised or locally advanced prostate cancer: An analysis of two randomised trials. Lancet Oncol 13:189-195, 2012
32. Ciani O, Davis S, Tappenden P, et al: Validation of surrogate endpoints in advanced solid tumors: Systematic review of statistical methods, results, and
implications for policy makers. Int J Technol Assess Health Care 30:312-324, 2014
33. The R Project for Statistical Computing: www.r-project.org.
34. Freedland SJ, Humphreys EB, Mangold LA, et al: Death in patients with recurrent prostate cancer after radical prostatectomy: Prostate-specific antigen
doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol 25:1765-1771, 2007
35. Van den Broeck T, van den Bergh RCN, Arfi N, et al: Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: A
systematic review. Eur Urol 75:967-987, 2019
3040 © 2020 by American Society of Clinical Oncology Volume 38, Issue 26
Xie et al
36. Li Y, Taylor JM: Predicting treatment effects using biomarker data in a meta-analysis of clinical trials. Stat Med 29:1875-1889, 2010
37. Morgans AK, Stockler MR: Patient-reported outcomes in metastatic castration-sensitive prostate cancer in the adjuvant setting. Eur Urol Focus 5:144-146, 2019
38. Woods BS, Sideris E, Sydes MR, et al: Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Modelling to estimate long-
term survival, quality-adjusted survival, and cost-effectiveness. Eur Urol Oncol 1:449-458, 2018
39. Francini E, Gray KP, Shaw GK, et al: Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in
a hospital-based registry. Prostate Cancer Prostatic Dis 22:420-427, 2019
40. Kelloff GJ, Coffey DS, Chabner BA, et al: Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer.
Clin Cancer Res 10:3927-3933, 2004
n n n
Journal of Clinical Oncology 3041
PSA is not a Surrogate for OS in Localized Prostate Cancer
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Event-Free Survival, a Prostate-Specific Antigen–Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer
Treated With Radiation
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted.
Relationships are self-held unless noted. I5 Immediate Family Member, Inst5My Institution. Relationships may not relate to the subject matter of this manuscript.
For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).
Meredith M. Regan
Consulting or Advisory Role: Ipsen (Inst)
Research Funding: Veridex (Inst), OncoGenex (Inst), Pfizer (Inst), Ipsen (Inst),
Novartis (Inst), Merck (Inst), Ferring (Inst), Celgene (Inst), AstraZeneca (Inst),
Pierre Fabre (Inst), Ipsen (Inst), Bayer (Inst), Bristol-Myers Squibb (Inst), Roche
(Inst), Astellas Pharma (Inst), Medivation (Inst), Janssen (Inst), Millenium
Pharamceuticals (Inst), Sanofi (Inst), Sotio (Inst), Dendreon (Inst), Pfizer (Inst),
TerSera (Inst)
Travel, Accommodations, Expenses: Bristol-Myers Squibb
Marc Buyse
Employment: IDDI
Stock and Other Ownership Interests: IDDI
Susan Halabi
Employment: ASCO Targeted Agent and Profiling Utilization Registry
Consulting or Advisory Role: Eisai, Ferring Pharmaceuticals, Bayer
Philip W. Kantoff
Leadership: Context Therapeutics
Stock and Other Ownership Interests: Placon, Druggablity Technologies,
Context Therapeutics, Seer
Consulting or Advisory Role: Bavarian Nordic, Janssen, Merck, OncoCellMDX,
Genentech/Roche, Tarveda Therapeutics, Druggablity Technologies, Progenity,
Context Therapeutics, GE Healthcare, Seer
Patents, Royalties, Other Intellectual Property: Method for Predicting the Risk
of Prostate Cancer Morbidity and Mortality, Predicting and Treating Prostate
Cancer, Methods for Predicting Likelihood of Responding to Treatment,
Chromosome Copy Number Gain as a Biomarker of Urothelial Carcinoma
Lethality, Drug Combinations to Treat Cancer, Somatic ERCC2 Mutations
Correlate with Cisplatin sensitivity in muscle-invasive Urothelial Carcinoma
(Patent), Up-to-Date Royalties, Wolters Kluwer Royalties, Methods and Kits for
Determining Sensitivity to Cancer Treatment, Composition and Methods for
Screening and Diagnosis of Prostate Cancer
Open Payments Link: https://openpaymentsdata.cms.gov/physician/55315/
summary
Oliver Sartor
Stock and Other Ownership Interests: Lilly, GlaxoSmithKline, AbbVie, Cardinal
Health, United Health Group, PSMA Therapeutics
Consulting or Advisory Role: Bayer, Johnson & Johnson, Sanofi, AstraZeneca,
Dendreon, Endocyte, Constellation Pharmaceuticals, Advanced Accelerator
Applications, Pfizer, Bristol-Myers Squibb, Bavarian Nordic, EMD Serono,
Astellas Pharma, Progenics, Noxo, Blue Earth Diagnostics, Myovant, Myriad
Genetics, Novartis, Clovis
Research Funding: Bayer (Inst), Johnson & Johnson (Inst), Sanofi (Inst),
Endocyte (Inst), Innocrin Pharma (Inst), Merck (Inst), InVitae (Inst), Constellation
Pharmaceuticals (Inst), Advanced Accelerator Applications (Inst), AstraZeneca
(Inst), Dendreon (Inst), Sotio
Expert Testimony: Sanofi




Consulting or Advisory Role: Compugen, WindMIL




Stock and Other Ownership Interests: Berry Consultants
Consulting or Advisory Role: Berry Consultants
Research Funding: Daiichi Sankyo
Travel, Accommodations, Expenses: Berry Consultants
Noel Clarke
Honoraria: Janssen-Cilag, Astellas Pharma, AstraZeneca
Speakers’ Bureau: AstraZeneca, Astellas Pharma, Bayer, Ferring, Ipsen, Sanofi,
Amgen, Janssen
Research Funding: AstraZeneca (Inst)
Travel, Accommodations, Expenses: Ipsen, Janssen, Sanofi
Richard De Abreu Lourenco
Consulting or Advisory Role: Vifor Pharma (I)
James Dignam
Consulting or Advisory Role: Merck, Celgene, Northwest Biotherapeutics
Mario Eisenberger
Leadership: Veru
Stock and Other Ownership Interests: Veru
Honoraria: Merck Sharp & Dohme, Bristol-Myers Squibb
Travel, Accommodations, Expenses: Veru
Nicholas James
Honoraria: Sanofi, Bayer, Oncogenex, Janssen, Astellas Pharma, Pierre Fabre
Consulting or Advisory Role: Sanofi, Bayer, Astellas Pharma, Janssen, Clovis,
EUSA Pharma, Pfizer
Speakers’ Bureau: Pierre Fabre, Ferring, Sanofi, Astellas Pharma, Janssen
Oncology
Research Funding: Janssen (Inst), Astellas Pharma (Inst), Pfizer (Inst), Sanofi
(Inst), Novartis (Inst)
Travel, Accommodations, Expenses: Sanofi, Janssen
Karim Fizazi
Honoraria: Janssen, Sanofi, Astellas Pharma, Bayer
Consulting or Advisory Role: Janssen Oncology, Bayer, Astellas Pharma, Sanofi,
Orion Pharma GmbH, Curevac (Inst), AstraZeneca (Inst), ESSA (Inst), Amgen
(Inst)
Travel, Accommodations, Expenses: Amgen, Janssen
Silke Gillessen
Honoraria: Janssen
Consulting or Advisory Role: Astellas Pharma (Inst), Advanced Accelerator
Applications, Roche, Janssen (Inst), Innocrin Pharma (Inst), Sanofi, Bayer (Inst),
Orion Pharma GmbH, Clovis Oncology (Inst), Menarini Silicon Biosystems (Inst),
Tolero Pharmaceuticals (Inst), Vaniam Group (Inst)
Patents, Royalties, Other Intellectual Property: Method for biomarker(WO
3752009138392 A1)
Other Relationship: ProteoMediX, Aranda (Inst)
Yohann Loriot
Honoraria: Sanofi, Pfizer
Consulting or Advisory Role: Janssen, Janssen (Inst), Astellas Pharma, Roche,
AstraZeneca, MSD Oncology, MSD Oncology (Inst), Clovis Oncology, Seattle
Genetics, Bristol-Myers Squibb
Research Funding: Sanofi (Inst), Janssen Oncology (Inst), MSD Oncology (Inst),
AstraZeneca (Inst), Clovis Oncology (Inst), Exelixis (Inst), Boehringer Ingelheim
(Inst), Incyte (Inst), Pfizer (Inst), Oncogenex (Inst), Medivation (Inst), CureVac
(Inst), Nektar (Inst)
Travel, Accommodations, Expenses: Astellas Pharma, Janssen Oncology,
Roche, MSD Oncology, AstraZeneca, Seattle Genetics
Nicolas Mottet
Honoraria: Janssen-Cilag, Astellas Pharma, Bayer, IPSEN, Sanofi/Aventis
Consulting or Advisory Role: Janssen-Cilag, Astellas Pharma, Bayer, Arquer
Howard Sandler
Stock and Other Ownership Interests: Radiogel
Consulting or Advisory Role: Janssen
Other Relationship: Caribou Publishing
Daniel E. Spratt
Consulting or Advisory Role: Blue Earth Diagnostics, Janssen Oncology,
AstraZeneca
Matthew R. Sydes
Honoraria: Lilly, Sanofi, Janssen, Janssen
Research Funding: Astellas Pharma, Janssen-Cilag, Pfizer, Novartis, Sanofi,
Clovis Oncology
© 2020 by American Society of Clinical Oncology Volume 38, Issue 26
Xie et al
Bertrand Tombal
Honoraria: Amgen, Astellas Pharma, Bayer, Ferring, Sanofi, Janssen, Pfizer,
Myovant Sciences
Consulting or Advisory Role: Astellas Pharma, Bayer, Ferring, Janssen, Takeda,
Steba Biotech, Sanofi
Speakers’ Bureau: Amgen, Janssen
Research Funding: Ferring (Inst)
Travel, Accommodations, Expenses: Amgen, Astellas Pharma, Bayer, Ferring,
Janssen, Sanofi
Scott Williams
Consulting or Advisory Role: Amgen, Janssen (Inst)
Travel, Accommodations, Expenses: Astellas Pharma
Christopher J. Sweeney
Stock and Other Ownership Interests: Leuchemix
Consulting or Advisory Role: Sanofi, Janssen Biotech, Astellas Pharma, Bayer,
Genentech/Roche, AstraZeneca, Pfizer, Amgen, Celgene, Lilly
Research Funding: Janssen Biotech (Inst), Astellas Pharma (Inst), Sanofi (Inst),
Bayer (Inst), Dendreon, Pfizer (Inst)
Patents, Royalties, Other Intellectual Property: Leuchemix, Parthenolide,
Dimethylaminoparthenolide.Exelixis: Abiraterone plus cabozantinib
combination
No other potential conflicts of interest were reported.
Journal of Clinical Oncology
PSA is not a Surrogate for OS in Localized Prostate Cancer
APPENDIX Writing Committee
Coordinating Center at Dana-Farber Cancer Institute. Christopher
J. Sweeney, Chair (Lank Center for Genitourinary Oncology, Dana-Farber
Cancer Institute, Boston, MA); Meredith M. Regan (Division of Bio-
statistics, Dana-Farber Cancer Institute, Boston, MA); Wanling Xie
(Division of Biostatistics, Dana-Farber Cancer Institute, Boston, MA).
Members Independent of Coordinating Center overseeing
Statistical Analysis Plan. Marc Buyse (International Drug De-
velopment Institute, Louvain la Neuve, Belgium); Susan Halabi (De-
partment of Biostatistics and Bioinformatics, Duke University,
Durham, NC); Philip W. Kantoff (Department of Medicine, Memorial
Sloan-Kettering Cancer Center, New York, NY, Prostate Cancer
Foundation, Santa Monica, CA); Oliver Sartor (Departments of Med-
icine & Urology, Tulane University, New Orleans, LA); Howard Soule
(Prostate Cancer Foundation, Santa Monica, CA).
External Review
Donald Berry (Department of Biostatistics, The University of Texas MD
Anderson Cancer Center); Noel Clarke (Urological Oncology, The
Christie NHS Foundation Trust, Manchester, United Kingdom); Lau-
rence Collette (EORTC Headquarters, Brussels, Belgium); Richard De
Abreu Lourenco (University of Technology Sydney, Sydney, NSW,
Australia); Mario Eisenberger (Sidney Kimmel Comprehensive Cancer
Center, Johns Hopkins University, Baltimore, MD); James Dignam
(Department of Public Health Science, University of Chicago, Chicago,
IL); Nicholas James (University Hospitals Birmingham NHS Foun-
dation Trust); Karim Fizazi (Department of Cancer Medicine, Institut
Gustave Roussy, Villejuif, France); Silke Gillessen (Division of Cancer
Sciences, University of Manchester and The Christie, Manchester,
United Kingdom, and Department of Oncology); Yohann Loriot (De-
partment of Cancer Medicine, Institut Gustave Roussy, Villejuif,
France); Nicolas Mottet (Urology Oncology, University JeanMonnet, St
Etienne, France); Wendy Parulekar (Canadian Cancer Trials Group,
Cancer Research Institute, Queen’s University, Kinston, Ontario,
Canada); Howard Sandler (Radiation Oncology, Cedars Sinai Medical
Center, Los Angeles, CA); Daniel E. Spratt (University of Michigan);
Matthew R. Sydes (MRC Clinical Trials Unit, Institute of Clinical Trials
and Methodology, UCL, London, United Kingdom); Bertrand Tombal
(Institut de Recherche Clinique, Université Catholique de Louvain,
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